Hypertension
Conditions
Brief summary
Evaluate the safety and anti-hypertensive efficacy of hyzaar(R) in patients with mild to moderate essential hypertension.
Interventions
DRUGMK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks
Sponsors
Organon and Co
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient is either receiving high blood pressure monotherapy or no treatment * Patient will have reached the legal age by the time enter the study * Patients diagnosed with mild to moderate essential high blood pressure or high blood pressure with other conditions such as diabetes or cardiovascular diseases and are taking high blood pressure medication (exclude diuretic), but did not meet treatment goal
Exclusion criteria
* Patient with high levels of uric acid in the blood who has received medications for uric acid in the urine within 3 months prior to enrollment * Patients who are hypersensitive to any component of the study medication * Patients who are hypersensitive to other sulfonamide-derived drugs * Patients with anuria (hyzaar(R) is not recommended for patients with hepatic impairment or severe renal impairment, creatinine clearance \</= 30 ml/min) * Unstable diabetes (hba1c \> 8%), or a change in diabetes medication during study treatment. patients with stable diabetes may enter the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure over 12 weeks | — |
| Safety and Tolerability. | — |
Outcome results
None listed